Welcome to our dedicated page for CLOVER HEALTH INVESTMENTS /DE SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CLOVER HEALTH INVESTMENTS /DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CLOVER HEALTH INVESTMENTS /DE's regulatory disclosures and financial reporting.
Jamie Reynoso reports an intention under Rule 144 to sell up to 4,839 shares of CLOV common stock through Morgan Stanley Smith Barney LLC, with an indicated value of $21,291.60. The notice also lists multiple prior common-stock sales between June 11 and July 15, 2026, some under 10b5-1 plans.
Clover Health Investments, Corp. reports a cybersecurity incident involving anomalous login activity detected on July 4, 2026 on certain information systems. An investigation, supported by third-party cybersecurity experts, determined that a threat actor accessed three non-managerial health plan employee accounts through social engineering.
The affected accounts were used for member visit-scheduling and broker-facing sales functions and had access to some personally identifiable information and protected health information, but no access to corporate financial or claims systems. Clover Health states that its rapid response contained and terminated the unauthorized access and, based on information currently available, it does not believe the incident has had, or is reasonably likely to have, a material impact on its business, financial condition, or results of operations. The company has notified law enforcement, is further hardening its IT environment, and will provide required notifications, including to impacted members, once its assessment of the scope and nature of any data access is complete.
Clover Health Investments CEO Andrew Toy reported a required sale of 62,711 Class A shares at a weighted average price of $4.67 per share to cover tax withholding from the vesting of 6.25% of RSUs originally granted on October 15, 2024. The company’s equity plan mandates these sell to cover trades, so they were not discretionary. After the sale, Toy directly holds 9,547,114 shares. Remaining RSUs vest in equal 6.25% quarterly installments through October 15, 2028, subject to continued service.
Clover Health Investments insider activity shows Wai Conrad, CEO of Counterpart Health, sold 24,215 Class A shares on July 15, 2026 at a weighted average $4.67, with prices from $4.67 to $4.73, solely to cover tax withholding on vesting of 6.25% of RSUs granted October 15, 2024. These mandated “sell to cover” trades under the company’s equity incentive plans are not discretionary. Afterward he held 1,145,699 shares directly and 1,390,056 shares indirectly through a family trust where he is co‑trustee, while the remaining RSUs vest quarterly in 6.25% installments through October 15, 2028.
Clover Health Investments, Corp. executive Jamie L. Reynoso reported an open-market sale of 13,119 shares of Class A Common Stock on July 15, 2026 at a weighted average price of $4.67 per share. The sale was a mandated "sell to cover" for tax withholding on RSU vesting and not a discretionary trade. Following the transaction, Reynoso holds 2,819,479 shares directly.
Clover Health Investments’ Chief Legal Officer Karen Soares reported an open-market sale of 10,519 shares of Class A common stock on July 15, 2026, at a weighted average price of $4.67 per share, within a $4.67–$4.73 range. According to the disclosure, the sale was mandated to cover tax withholding obligations arising from the vesting of restricted stock units granted on October 15, 2024, under the company’s equity incentive plans and does not represent a discretionary trade. After this tax-related sale, Soares continues to hold 1,557,222 shares directly. The remaining RSUs vest quarterly in 6.25% installments through October 15, 2028, subject to continued service.
Clover Health’s interim CFO, Joseph Clay, reported an open-market sale of 4,630 shares of Class A Common Stock on July 15, 2026 at a weighted average price of $4.67 per share. Footnotes state the sale was a mandated sell-to-cover transaction to satisfy tax withholding on the vesting of 6.25% of his restricted stock units granted on October 15, 2024. The RSUs continue to vest quarterly in 6.25% installments through October 15, 2028, subject to his continued service. Following the sale, he holds 1,212,954 shares directly.
An affiliate of ticker CLOV plans to sell 10,192 shares of Class A Common Stock through Morgan Stanley Smith Barney LLC on Nasdaq around July 15, 2026, with an aggregate market value of 47,698.56.
Total Class A shares outstanding are 430,969,398; this is a baseline figure, not the amount being sold. Over the past three months, 4,681 shares were sold for 21,579.41 under a 10b5-1 plan.
An affiliate of CLOV plans to sell 12,712 shares of its Class A common stock, with an aggregate market value of $59,492.16, through Morgan Stanley Smith Barney LLC around July 15, 2026 on Nasdaq. These shares were acquired from the issuer as restricted stock units granted as compensation. Recent 10b5-1 sales by Jamie Reynoso over June–July 2026 include multiple Class A common stock transactions, such as 7,289 shares on June 11, 2026 and 6,350 shares on June 15, 2026.